Sudarshan Pharma Industries' Q2 FY 2026-27 Quarterly Results

Result Summary

• Sudarshan Pharma Industries Ltd reported a 24.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 28.2%.
• Its expenses for the quarter were up by 23.8% QoQ and 25.0% YoY.
• The net profit increased 38.7% QoQ and increased 101.0% YoY.
• The earnings per share (EPS) of Sudarshan Pharma Industries Ltd stood at 0.31 during Q2 FY 2026-27.

Financial Statments for Q2 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sudarshan Pharma Industries Ltd is a company involved in the pharmaceutical sector, primarily engaged in the development, manufacturing, and distribution of pharmaceutical products and related services. The company operates within the pharmaceutical industry, which is characterized by high levels of research and development, regulatory compliance, and product innovation. Sudarshan Pharma Industries Ltd offers a range of pharmaceutical formulations and intermediates. While specific recent developments about the company are not provided in the given data, entities in this sector often focus on expanding their product portfolio, enhancing production capabilities, and entering new markets to sustain growth.

Revenue

In Q2FY27, Sudarshan Pharma Industries Ltd reported a total income of ₹218.90 crores, marking a quarter-over-quarter (QoQ) increase of 24.6% from ₹175.64 crores in Q1FY27. Compared to the previous year, Q2FY26, where the total income was ₹170.73 crores, the year-over-year (YoY) growth was 28.2%. This indicates a robust growth in the company's revenue streams over both the quarterly and yearly periods. The increase in total income reflects the company's ability to enhance its market presence and revenue-generating operations within the pharmaceutical industry.

Profitability

The company's profitability metrics exhibited significant improvements during Q2FY27. The profit before tax stood at ₹10.80 crores, which represents a 43.8% increase from ₹7.51 crores in Q1FY27. When compared to Q2FY26, where the profit before tax was ₹4.23 crores, there is a notable YoY increase of 155.3%. After accounting for taxes, the profit after tax for Q2FY27 was ₹7.78 crores, which is a 38.7% QoQ increase from ₹5.61 crores in Q1FY27 and a 101.0% YoY increase from ₹3.87 crores in Q2FY26. This substantial improvement reflects the company's enhanced profitability performance over the respective periods.

Operating Metrics

The total expenses for Sudarshan Pharma Industries Ltd in Q2FY27 were ₹208.11 crores, representing a 23.8% increase from ₹168.14 crores in Q1FY27. Compared to Q2FY26, where total expenses were ₹166.50 crores, there is a 25.0% YoY increase. The company's earnings per share (EPS) for Q2FY27 was reported at ₹0.31, which is a 34.8% QoQ increase from ₹0.23 in Q1FY27 and a 93.8% YoY increase from ₹0.16 in Q2FY26. The tax expense for Q2FY27 was ₹3.02 crores, a 58.9% QoQ increase from ₹1.90 crores in Q1FY27 and a significant 738.9% YoY increase from ₹0.36 crores in Q2FY26. These figures illustrate the company's operational scale and efficiency improvements over the analyzed periods.